Geron Corporation

For the past three years, Geron has been proud to be a National Sponsor for #MoveForMDS walks, organized by MDS Foundation, Inc., which supports efforts to unite communities, drive awareness and accelerate research for myelodysplastic syndromes (#MDS). The next walk is on August 25 in Chicago! Learn more and sign up for an upcoming walk: https://moveformds.org/

Powered by pioneering science, grounded in world-class expertise, and driven by purpose, Geron aims to change lives by changing the course of #BloodCancer. Learn more about our story: https://lnkd.in/ecdpB8p2

Meet Leslie Cherette, Director, CMC Program Management. Leslie’s childhood passion for science led her to a career in STEM. She says Geron provided her the opportunity to make a more tangible impact in the patient community, particularly in areas with unmet need.    This #Juneteenth, Leslie says she is proud to be the first African American woman in her program management position at Geron, and of her work in Geron’s recent FDA approval.    “I am inspired by a dedicated and driven group of people who motivate me to believe that we can accomplish anything, including bringing this therapy, and others like it, to some of the most underserved patient populations.”  

Geron will be hosting a conference call for investors scheduled for 8 a.m. ET on June 7 to discuss today’s FDA approval. Learn more: https://lnkd.in/e9VZx33X

BREAKING NEWS: We are pleased to share that the U.S. Food and Drug Administration (FDA) has approved our medicine for adults with lower-risk MDS with transfusion-dependent anemia. Learn more: https://lnkd.in/e9CPbpAi

News from #ASCO24: The team is on the ground at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago! Come visit us at Booth # 10105 — we’ve been enjoying our time collaborating with our peers in the #oncology community.    Additionally, Geron presented a poster with data from our IMerge Phase 3 clinical trial on the efficacy of our investigational telomerase inhibitor on red blood cell-transfusion in lower-risk myelodysplastic syndromes (#MDS) patients. Learn more: https://lnkd.in/eHUq3PSU

For more than 30 years, we’ve researched, adapted, and even challenged conventions in pursuit of new possibilities for patients with blood cancer.     Learn more about Geron’s dedication to changing the course of #BloodCancer: https://lnkd.in/ecxHSVKg  

Meet JR Raelin, MBA, PMP, PMI-ACP, Director, Commercial Data and Technology Operations.   For JR, it’s the patients and the opportunity to change lives that inspires him throughout his workday. He also cites “the great people I met during the interview process” as one of the primary reasons he joined the Geron team.    “Each day offers its own unique challenges,” he says. “But my day is focused on getting our applications, systems, and data ready for our expected transition to a commercial company. Each day combines strategy with meetings, hands-on problem solving, and team collaboration.”

Today is #ClinicalTrialsDay, where we recognize and honor the crucial work of our teams in driving forward healthcare advancements. Through unwavering dedication and innovative thinking, we aim to push boundaries and transform lives through rigorous research and development. Learn more: https://lnkd.in/ekZGCF9h

Earlier this week, Vice President of Investor Relations and Corporate Communications Aron Feingold attended Fierce Life Sciences Events PR & Communications Summit West, where she participated on a panel, speaking about the power of communications professionals to drive value and strategy in biotech, and led a roundtable discussion on metrics and measurement to demonstrate that value to critical stakeholders.